Table 1:

Current Checkpoint Inhibitor Trials for Classical Hodgkin Lymphoma

Clinicaltrials.gov Identifier	Drug	Concept	Phase	Disease	Included Ages
Relapsed/Refractory
NCT02603419	Avelumab	PD-L1 antibody	Ib	cHL	Adults
NCT02684292	Pembrolizumab vs BV	PD-1 antibody compared to anti-CD30 ADC	III	cHL	Adults
NCT02572167	Nivolumab and BV	PD-1 antibody combined with anti-CD30 ADC	I/II	cHL	Adults
NCT02927769	Nivolumab and BV (followed by BV and bendamustine in those with suboptimal response)	PD-1 antibody combined with anti-CD30 ADC after failure of first line therapy	II	cHL	Children and adults (5 years to 30 years)
NCT02940301	Nivolumab and ibrutinib	PD-1 antibody combined with BTK inhibitor	II	cHL and NLPHL	Adults
NCT02665650	Pembrolizumab and AFM13	PD-1 antibody combined with bispecific anti-CD30/CD16A antibody	Ib	cHL	Adults
NCT03015896	Nivolumab and lenalidomide	PD-1 antibody and immunomodulator	I/II	HL and NHL	Adults
NCT02875067	Pembrolizumab and lenalidomide	PD-1 antibody and immunomodulator	I/II	HL and NHL	Adults
NCT03016871	Nivolumab and ICE	PD-1 antibody and chemotherapy as second line therapy	II	cHL	Adults, children (15 years and older)
NCT03077828	Pembrolizumab and ICE	PD-1 antibody and chemotherapy	II	cHL	Adults
NCT01896999	Nivolumab, ipilimumab, BV	PD-1 antibody, CTLA-4 antibody and anti-CD30 ADC	I	cHL	Adults
Consolidation therapy after ASCT
NCT02362997	Pembrolizumab	PD-1 antibody	II	cHL, DLBCL, PTCL	Adults
NCT03057795	Nivolumab and BV	PD-1 antibody and anti-CD30 ADC	II	cHL	Adults
First Line
NCT03033914	A(B)VD followed by nivolumab	Conventional chemotherapy followed by PD-1 antibody	I	cHL (high risk)	Adults (2nd cohort for patients 60 and older)
NCT03004833	AVD and nivolumab	PD-1 antibody and conventional chemotherapy	II	cHL (early stage unfavorable)	Adults (18 to 60 years)
NCT02758717	Nivolumab and BV	PD-1 antibody and anti-CD30 ADC	II	cHL (unable to receive standard chemotherapy)	Children, adults (focus on age 60 and older)

cHL = classical Hodgkin lymphoma, BV = brentuximab vedotin, ADC = antibody drug conjugate, HL= Hodgkin lymphoma, NHL = Non-Hodgkin lymphoma, NLPHL = nodular lymphocyte predominant Hodgkin lymphoma, ICE = ifosfamide, carboplatin, etoposide, ASCT = autologous stem cell transplant, A(B)VD = doxorubicin, (bleomycin), vinblastine, dacarbazine